Evidence map›Paper›PMID 33672669›Full record

ArticleAntibiotics (Basel, Switzerland)2021

A Novel Ivermectin-Derived Compound D4 and Its Antimicrobial/Biofilm Properties against MRSA.

Xinyi Tan, Haoji Xie, Bin Zhang, Jiale Zhou, Zhende Dou, Xiao Wang, Ning Wang

Open access · goldAbstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Proteomic Comparison of Ivermectin Sensitive and ResistantAntibiotics (Basel, Switzerland) · 2022
    Article
  7. Review
  8. Article
  9. International journal of molecular sciences · 2021
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Xinyi TanImmunology Innovation Team, School of medicine, Ningbo University, Ningbo 315211, Zhejiang, China.
Haoji XieImmunology Innovation Team, School of medicine, Ningbo University, Ningbo 315211, Zhejiang, China.
Bin ZhangLi Dak Sum Yip Yio Chin Kenneth Li Marine Biopharmaceutical Research Center, College of Food and Pharmaceutical Sciences, Ningbo University, Ningbo 315800, Zhejiang, China.ORCID 0000-0002-4371-4746
Jiale ZhouImmunology Innovation Team, School of medicine, Ningbo University, Ningbo 315211, Zhejiang, China.
Zhende DouLi Dak Sum Yip Yio Chin Kenneth Li Marine Biopharmaceutical Research Center, College of Food and Pharmaceutical Sciences, Ningbo University, Ningbo 315800, Zhejiang, China.
Xiao WangImmunology Innovation Team, School of medicine, Ningbo University, Ningbo 315211, Zhejiang, China.
Ning WangInstitute of Drug Discovery Technology, Ningbo University, Ningbo 315211, Zhejiang, China.ORCID 0000-0002-5625-5358
Ningbo University · CN

Funding

National Natural Science Foundation of China 82002190Natural Science Foundation of Ningbo 2019A610196Research Fund of Ningbo University 421807120, 421906052, 422003802
6 · The paper itself

Abstract

Methicillin-resistant

Indexed as

antibacterialantibiofilmivermectin derivativemechanismsMRSA

Identifiers

PMID33672669
PMCPMC7924331
OpenAlexW3130523431

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.